Results 111 to 120 of about 6,421 (186)

Budget Impact of Adopting Nirmatrelvir-Ritonavir for Treating COVID-19 in a Large Integrated Healthcare System. [PDF]

Open Forum Infect Dis
Bui DP, Hynes DM, Wong E, Vergun R, Yan L, Li Y, Rajeevan N, Berry K, Lin HM, Huang Y, Govier DJ, Aslan M, Ioannou G, Bajema KL.   +13 more
europepmc   +1 more source

Complete Heart Block Triggered by Nirmatrelvir-Ritonavir and Verapamil. [PDF]

JACC Case Rep
Offord E, Nabi M, Mankbadi M, Marchetta A, Rosenthal L.   +4 more
europepmc   +1 more source

A Retrospective Observational Study on COVID-19 Patients Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID). [PDF]

Pulm Ther
Murad MM, Atkin SL, Wasif PW, Behzad AA, Husain AMJA, d'Hellencourt FL, Joury J, Aziz MA, Haridy H, Spinardi J, Wang L, Boland F, Kyaw MH, Al-Qahtani M.   +13 more
europepmc   +1 more source

Real-World Effectiveness of Nirmatrelvir-Ritonavir Against Severe Outcomes of COVID-19 in Taiwan: A Nationwide Population-Based Cohort Study. [PDF]

Open Forum Infect Dis
Kuo RN, Chen W, Shau WY, Chang SC.
europepmc   +1 more source

Effectiveness of Antivirals Nirmatrelvir-Ritonavir and Molnupiravir in Viral Sepsis: Retrospective Cohort Study.

JMIR Public Health Surveill
Lee TTL, Lyu AC, Jiang TT, Chan SCL, Chan CY, Yip ETF, Luk LYF, Ho JWK, So KWL, Tsui OWK, Lam ML, Lee SY, Yamamoto T, Tong CK, Wong MS, Wong ELY, Wai AKC, Rainer TH.   +17 more
europepmc   +1 more source

Pharmacovigilance of Drug-Drug Interactions with Nirmatrelvir/Ritonavir. [PDF]

Infect Dis Ther
Hendrick V, Pohorylo E, Merchant L, Gerhart J, Arham IN, Draica F, Quercia R, Ayoub A, Mehta R.   +8 more
europepmc   +1 more source

Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: network meta-analysis and budget impact analysis [PDF]

Baldi, Ileana, Berti, Giacomo, Cattelan, Anna Maria, Chinellato, Gianmarco, Mazzitelli, Maria, Mengato, Daniele, Ocagli, Honoria, Venturini, Francesca   +7 more
core   +1 more source

Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study. [PDF]

Front Pharmacol
Shi H, Zhang X, Kong Q, Yu L, Yu Z.
europepmc   +1 more source

Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19. [PDF]

PLoS One
Yan H, Hu S, Zhang H, Zhou Y, Fu R, Xu P, Cai H, Li X, Lan G.   +8 more
europepmc   +1 more source

The Impact of COVID-19 and the Practical Importance of Vaccinations and Nirmatrelvir/Ritonavir for Patients with Cardiovascular Disease. [PDF]

Vaccines (Basel)
Wełnicki M, Mamcarz A, Kuchar E, Mitkowski P, Jaroszewicz J, Tomasiewicz K, Gąsior M, Leszek P, Kamiński KA, Wysocki J.   +9 more
europepmc   +1 more source